SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.
ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.